| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | BTB/POZ domain-containing protein KCTD20, Potassium channel tetramerization domain containing 20, KCTD20, C6orf69 |
| Entrez GeneID | 222658 |
| WB Predicted band size | 47.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Mouse |
| Immunogen | This KCTD20 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 313-341 amino acids from the C-terminal region of human KCTD20. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇关于KCTD20抗体的模拟参考文献(注：经核实，目前公开数据库中KCTD20特异性抗体的研究较少，以下内容为学术假设性示例)：
1. **文献名称**：KCTD20 regulates mTOR signaling pathway in hepatocellular carcinoma
**作者**：Li X, et al.
**摘要**：本研究通过构建KCTD20特异性抗体，发现其在肝癌组织中表达下调。实验证实KCTD20通过结合RAPTOR蛋白抑制mTORC1复合体活性，抗体染色显示其表达水平与患者预后呈正相关(Cancer Res. 2020)。
2. **文献名称**：Structural characterization of KCTD20 and its interaction with Cullin3
**作者**：Gupta R, et al.
**摘要**：利用兔源多克隆抗体解析KCTD20的晶体结构，证明其BTB结构域介导与Cullin3的相互作用。抗体阻断实验表明该互作影响泛素化降解通路(J Biol Chem. 2018)。
3. **文献名称**：KCTD20 antibody reveals stage-specific expression in mouse spermatogenesis
**作者**：Sato K, et al.
**摘要**：开发鼠抗KCTD20单克隆抗体，免疫组化显示其在精子发生中期特异性高表达，敲除模型证实其参与顶体形成过程(Dev Biol. 2019)。
注：建议通过PubMed使用关键词"KCTD20 antibody"或"KCTD20 immunolocalization"检索最新实证研究，部分商业抗体公司(如Abcam、Santa Cruz)的产品说明可能包含应用文献。
The KCTD20 antibody is a tool used to detect the potassium channel tetramerization domain-containing protein 20 (KCTD20), a member of the BTB/POZ domain-containing protein family. KCTD20 is involved in regulating cellular processes such as ubiquitination, signal transduction, and autophagy. It interacts with cullin-3 (CUL3), a component of the E3 ubiquitin ligase complex, to mediate substrate-specific protein degradation via the ubiquitin-proteasome system. KCTD20 has been implicated in modulating the B-cell receptor (BCR) signaling pathway, where it may influence immune responses and lymphocyte activation. Additionally, studies suggest its role in autophagy by interacting with autophagy-related proteins, impacting cellular stress responses and homeostasis.
Research using KCTD20 antibodies has helped elucidate its expression patterns, subcellular localization (primarily cytoplasmic), and tissue distribution, with notable presence in immune and neural tissues. Dysregulation of KCTD20 is linked to pathological conditions, including cancers and neurodegenerative diseases, making it a potential biomarker or therapeutic target. The antibody is widely employed in techniques like Western blotting, immunohistochemistry, and immunofluorescence to study protein-protein interactions, expression levels, and functional mechanisms in both physiological and disease contexts. Commercial availability of monoclonal and polyclonal KCTD20 antibodies facilitates ongoing research into its diverse roles in cellular regulation and disease pathways.
×
